Drug-induced liver injury in older adults

Therapeutic Advances in Drug Safety

Volumn 1, Issue 2, 2010, Pages 65-77

  Mitchell, Sarah J ^a   Hilmer, Sarah N ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

ageing; drug induced liver injury; frailty; idiosyncratic; pharmacovigilance

Indexed keywords

EID: 84993808216     PISSN: 20420986     EISSN: 20420994     Source Type: Journal    
DOI: 10.1177/2042098610386281     Document Type: Review

References (98)

1. Andrade R.J. Lucena M.I. Fernandez M.C. Pelaez G. Pachkoria K. Garcia-Ruiz E. (2005) Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 129: 512–521.
2. Andrews E. Armstrong M. Tugwood J. Swan D. Glaves P. Pirmohamed M. (2010) A role for the pregnane X receptor in flucloxacillin-induced liver injury. Hepatology 51: 1656–1664.
3. Andrews E. Daly A.K. (2008) Flucloxacillin-induced liver injury. Toxicology 254: 158–163.
4. Avorn J. Shrank W.H. (2008) Adverse Drug Reactions in Elderly People: A substantial cause of preventable illness. Bmj 336: 956–957.
5. Bales C.W. Ritchie C.S. (2002) Sarcopenia, weight loss, and nutritional frailty in the elderly. Ann Rev Nutrition 22: 309–323.
6. Banks A.T. Zimmerman H.J. Ishak K.G. Harter J.G. (1995) Diclofenac-associated hepatotoxicity: Analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. Hepatology 22: 820–827.
7. Björnsson E. Jerlstad P. Bergqvist A. Olsson R. (2005) Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scand J Gastroenterol 40: 1095–1101.
8. Björnsson E. Olsson R. (2006) Suspected drug-induced liver fatalities reported to the WHO database. Digest Liver Dis 38: 33–38.
9. Boelsterli U.A. (2003) Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol Appl Pharmacol 192: 307–322.
10. Boelsterli U.A. Lim P.L.K. (2007) Mitochondrial abnormalities–a link to idiosyncratic drug hepatotoxicity? Toxicol Appl Pharmacol 220: 92–107.
11. Bolesta S. Haber S.L. (2002) Hepatotoxicity associated with chronic acetaminophen administration in patients without risk factors. Ann Pharmacother 36: 331–333.
12. Bort R. Macé K. Boobis A. Gómez-Lechón M.-J. Pfeifer A. Castell J. (1999) Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol 58: 787–796.
13. Burgess C.L. Holman C.D. Satti A.G. (2005) Adverse drug reactions in older Australians, 1981–2002. Med J Aust 182: 267–270.
14. Burton B. (2007) Australian drugs regulator cancels registration of COX 2 inhibitor. BMJ 335(7616): 363.
15. Chitturi S. Farrell G. (2000a) Drug-induced liver disease. Current Treatment Options Gastroenterol 3: 457–462.
16. Chitturi S. Farrell G.C. (2000b) Herbal hepatotoxicity: An expanding but poorly defined problem. J Gastroenterol Hepatol 15: 1093–1099.
17. Clark J.M. Brancati F.L. Diehl A.M. (2003) The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 98: 960–967.
18. Daly A.K. Donaldson P.T. Bhatnagar P. Shen Y. Pe'er I. Floratos A. (2009) HLA-B[ast]5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 41: 816–819.
19. Devereaux B.M. Crawford D.H.G. Purcell P. Powell L.W. Roeser H.P. (1995) Flucloxacillin associated cholestatic hepatitis–an Australian and Swedish epidemic. Eur J Clin Pharmacol 49: 81–85.
20. Elinav E. Ackerman Z. Maaravi Y. Ben-Dov I.Z. Ein-Mor E. Stessman J. (2006) Low alanine aminotransferase activity in older people is associated with greater long-term mortality. J Am Geriatrics Soc 54: 1719–1724.
21. Fisher A.A. Le Couteur D.G. (2001) Nephrotoxicity and hepatotoxicity of histamine H2 receptor antagonists. Drug Safety 24: 39–57.
22. Fried L.P. Tangen C.M. Walston J. Newman A.B. Hirsch C. Gottdiener J. (2001) Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56: M146–M156.
23. Gonzalez-Martin G. Dominguez A.R. Guevara A. (1997) Pharmacokinetics and hepatotoxicity of diclofenac using an isolated perfused rat liver. Biomed Pharmacother 51: 170–175.
24. Hämmerlein A. Derendorf H. Lowenthal D.T. (1998) Pharmacokinetic and pharmacodynamic changes in the elderly. Clinical implications. Clin Pharmacokin 35: 49–64.
25. Hauben M. Aronson J.K. (2007) Gold standards in pharmacovigilance–the use of definitive anecdotal reports of adverse drug reactions as pure gold and high-grade ore. Drug Safety 30: 645–655.
26. Heaton P.C. Cluxton R.J. Jr Moomaw C.J. (2003) Acetaminophen overuse in the Ohio Medicaid population. J Am Pharm Assoc 43(6): 680–684.
27. Hilmer S.N. (2008) ADME-tox issues for the elderly. Expert Opin Drug Metab Toxicol 4: 1321–1331.
28. Hilmer S.N. Cogger V.C. Fraser R. McLean A.J. Sullivan D. Le Couteur D.G. (2005a) Age-related changes in the hepatic sinusoidal endothelium impede lipoprotein transfer in the rat. Hepatology 42: 1349–1354.
29. Hilmer S.N. Cogger V.C. Le Couteur D.G. (2007a) Basal activity of Kupffer cells increases with old age. J Gerontol A Biol Sci Med Sci 62: 973–978.
30. Hilmer S.N. McLachlan A.J. Le Couteur D.G. (2007b) Clinical pharmacology in the geriatric patient. Fundam Clin Pharmacol 21: 217–230.
31. Hilmer S.N. Shenfield G.M. Le Couteur D.G. (2005b) Clinical implications of changes in hepatic drug metabolism in older people. Therap Clin Risk Manag 1: 151–156.
32. Holt M.P. Ju C. (2006) Mechanisms of drug-induced liver injury. AAPS J 8: E48–E54.
33. Huang Y.-S. Chern H.-D. Su W.-J. Wu J.-C. Chang S.-C. Chiang C.-H. (2003) Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 37: 924–930.
34. Hussaini S.H. Farrington E.A. (2007) Idiosyncratic drug-induced liver injury: an overview. Expert Opin Drug Safety 6: 673–684.
35. Jollow D.J. Thorgeirsson S.S. Potter W.Z. Hashimoto H. Mitchell J.R. (1974) Acetaminophen-Induced Hepatic Necrosis. Pharmacology 12: 251–271.
36. Kaplowitz N. (2001) Drug-induced liver disorders–implications for drug development and regulation. Drug Safety 24: 483–490.
37. Kinirons M.T. Crome P. Kinirons M.T. Crome P. (1997) Clinical pharmacokinetic considerations in the elderly. An update. Clin Pharmacokin 33: 302–312.
38. Klotz U. (1998) Effect of age on pharmacokinetics and pharmacodynamics in man. Int J Clin Pharmacol Therapeut 36: 581–585.
39. Kretzrommel A. Boelsterli U.A. (1993) Diclofenac Covalent protein binding is dependent on acyl glucuronide formation and is inversely Related to P450-mediated acute cell injury in cultured rat hepatocytes. Toxicol Appl Pharmacol 120: 155–161.
40. Kumar R. Shalimar Bhatia V. Khanal S. Sreenivas V. Gupta S.D. (2010) Antituberculosis therapy-induced acute liver failure: Magnitude, profile, prognosis, and predictors of outcome. Hepatology 51: 1665–1674.
41. Kwan D. Bartle W.R. Walker S.E. (1995) Abnormal serum transaminases following therapeutic doses of acetaminophen in the absence of known risk factors. Digest Dis Sci 40: 1951–1955.
42. Laine L. Goldkind L. Curtis S.P. Connors L.G. Yanqiong Z. Cannon C.P. (2009) How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial. Am J Gastroenterol 104: 356–362.
43. Lakehal F. Dansette P.M. Becquemont L. Lasnier E. Delelo R. Balladur P. (2001) Indirect cytotoxicity of flucloxacillin toward human biliary epithelium via metabolite formation in hepatocytes. Chem Res Toxicol 14: 694–701.
44. Lang C.A. Naryshkin S. Schneider D.L. Mills B.J. Lindeman R.D. (1992) Low blood glutathione levels in healthy aging adults. J Lab Clin Med 120: 720–725.
45. Le Couteur D.G. Cogger V.C. Markus A.M.A. Harvey P.J. Yin Z.-L. Ansselin A.D. (2001) Pseudocapillarization and associated energy limitation in the aged rat liver. Hepatology 33: 537–543.
46. Le Couteur D.G. Fraser R. Cogger V.C. McLean A.J. (2002) Hepatic pseudocapillarisation and atherosclerosis in ageing. Lancet 359: 1612–1615.
47. Le Couteur D.G. McLean A.J. (1998) The aging liver. Drug clearance and an oxygen diffusion barrier hypothesis. Clin Pharmacokin 34: 359–373.
48. Lee W.M. (2003) Drug-induced hepatotoxicity. N Engl J Med 349: 474–485.
49. Lindley C.M. Tully M.P. Paramsothy V. Tallis R.C. (1992) Inappropriate medication is a major cause of adverse drug reactions in elderly patients. Age Ageing 21: 294–300.
50. López-Lluch G. Irusta P.M. Navas P. de Cabo R. (2008) Mitochondrial biogenesis and healthy aging. Exp Gerontol 43: 813–819.
51. Maddrey W.C. (2005) Drug-induced hepatotoxicity: 2005. J Clin Gastroenterol 39(4 Suppl. 2): S83–S89.
52. McLachlan A.J. Hilmer S.N. Le Couteur D.G. (2009) Variability in response to medicines in older people: phenotypic and genotypic factors. Clin Pharmacol Therapeut 85: 431–433.
53. McLean A.J. Le Couteur D.G. (2004) Aging biology and geriatric clinical pharmacology. Pharmacol Rev 56: 163–184.
54. Miner D.J. Kissinger P.T. (1979) Evidence for the involvement of N-acetyl-p-quinoneimine in acetaminophen metabolism. Biochem Pharmacol 28: 3285–3290.
55. Mitchell J.R. Jollow D.J. Potter W.Z. Davis D.C. Gillette J.R. Brodie B.B. (1973) Acetaminophen-induced hepatic necrosis I. Role of drug metabolism. J Pharmacol Exp Ther 187: 185–194.
56. Mitchell S.J. Hilmer S.N. McLachlan A.J. (2009a) Clinical pharmacology of analgesics in old age and frailty. Rev Clin Gerontol 19: 103–118.
57. Mitchell S.J. Hilmer S.N. Murnion B.P. Matthews S. (2010a) Hepatotoxicity of therapeutic short-course paracetamol in hospital inpatients: impact of ageing and frailty. J Clin Pharm Therapeut. in press.
58. Mitchell S.J. Huizer-Pajkos A. Cogger V.C. McLachlan A.J. Le Couteur D.G. Hilmer S.N. (2010b) Poloxamer 407 increases the recovery of paracetamol in the isolated perfused rat liver. J Pharmaceut Sci. in press.
59. Mitchell S.J. Murnion B.P. Matthews S.T. Hilmer S.N. (2009b) Compliance with paracetamol prescribing policies at a Sydney hospital. J Pharm Pract Res 39: 124–129.
60. Moore T.J. Cohen M.R. Furberg C.D. (2007) Serious adverse drug events reported to the Food and Drug Administration, 1998–2005. Arch Intern Med 167(16): 1752–1759.
61. Myers R.P. Li B. Fong A. Shaheen A.A. Quan H. (2007) Hospitalizations for acetaminophen overdose: a Canadian population-based study from 1995 to 2004. BMC Public Health 7: 143.
62. Myers R.P. Shaheen A.A. Li B. Dean S. Quan H. (2008) Impact of liver disease, alcohol abuse, and unintentional ingestions on the outcomes of acetaminophen overdose. Clin Gastroenterol Hepatol 6: 918–925. quiz 837.
63. Naisbitt D.J. Sanderson L.S. Meng X.L. Stachulski A.V. Clarke S.E. Park B.K. (2007) Investigation of the immunogenicity of diclofenac and diclofenac metabolites. Toxicol Lett 168: 45–50.
64. Pande J.N. Singh S.P.N. Khilnani G.C. Khilnani S. Tandon R.K. (1996) Risk factors for hepatotoxicity from antituberculosis drugs: a case–control study. Thorax 51: 132–136.
65. Perera V. Bajorek B.V. Matthews S. Hilmer S.N. (2009) The impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillation. Age Ageing 38: 156–162.
66. Ponsoda X. Bort R. Jover R. Gómez-lechón M.J. Castell J.V. (1995) Molecular mechanism of diclofenac hepatotoxicity: Association of cell injury with oxidative metabolism and decrease in ATP levels. Toxicol In Vitro 9: 439–444.
67. Prescott L.F. (1983) Paracetamol overdosage. Pharmacological considerations and clinical management. Drugs 25: 290–314.
68. Prescott L.F. (2000) Therapeutic misadventure with paracetamol: fact or fiction? Am J Therapeut 7: 99–114.
69. Pugh A.J. Barve A.J. Falkner K. Patel M. McClain C.J. (2009) Drug-induced hepatotoxicity or drug-induced liver injury. Clin Liver Dis 13: 277.
70. Rikans L.E. Moore D.R. (1988) Acetaminophen hepatotoxicity in aging rats. Drug Chem Toxicol 11: 237–247.
71. Rockwood K. Song X. MacKnight C. Bergman H. Hogan D.B. McDowell I. (2005) A global clinical measure of fitness and frailty in elderly people. CMAJ 173: 489–495.
72. Rostom A. Goldkind L. Laine L. (2005) Nonsteroidal anti-inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients. Clin Gastroenterol Hepatol 3: 489–498.
73. Roth R.A. Ganey P.E. (2010) Intrinsic versus idiosyncratic drug-induced hepatotoxicity–two villains or one? J Pharmacol Exp Therapeut 332: 692–697.
74. Routledge P.A. O'Mahony M.S. Woodhouse K.W. (2004) Adverse drug reactions in elderly patients. Br J Clin Pharmacol 57: 121–126.
75. Rowden A.K. Norvell J. Eldridge D.L. Kirk M.A. (2006) Acetaminophen Poisoning. Clin Lab Med 26: 49–65.
76. Rumack B.H. Matthew H. (1975) Acetaminophen poisoning and toxicity. Pediatrics 55: 871–876.
77. Russmann S. Kaye J.A. Jick S.S. Jick H. (2005) Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: Cohort study using data from the UK General Practice Research Database. Br J Clin Pharmacol 60: 76–82.
78. Schenker S. Martin R.R. Hoyumpa A.M. (1999) Antecedent liver disease and drug toxicity. J Hepatol 31: 1088–1097.
79. Schmidt L.E. (2005) Age and paracetamol self-poisoning. Gut 54: 686–690.
80. Schwartz J.B. (2006) Erythromycin breath test results in elderly, very elderly, and frail elderly persons. Clin Pharmacol Ther 79(5): 440–448.
81. Schwartz J.B. Verotta D. (2009) Population analyses of atorvastatin clearance in patients living in the community and in nursing homes. Clin Pharmacol Therapeut 86: 497–502.
82. Shen S. Marchick M.R. Davis M.R. Doss G.A. Pohl L.R. (1999) Metabolic activation of diclofenac by human cytochrome p450 3a4: role of 5-hydroxydiclofenac. Chem Res Toxicol 12: 214–222.
83. Stevens J.L. Baker T.K. (2009) The future of drug safety testing: expanding the view and narrowing the focus. Drug Discov Today 14: 162–167.
84. Stio M. Iantomasi T. Favilli F. Marraccini P. Lunghi B. Vincenzini M.T. (1994) Glutathione metabolism in heart and liver of the aging rat. Biochim Biol Cell 72: 58–61.
85. Strom B.L. (2006) How the US drug safety system should be changed. JAMA 295: 2072–2075.
86. Thomas S.H. (1993) Paracetamol (acetaminophen) poisoning. Pharmacol Ther 60: 91–120.
87. Wang H. Liu H. Liu R.-M. (2003) Gender difference in glutathione metabolism during aging in mice. Exp Gerontol 38: 507–517.
88. Ward B. Alexander-Williams J.M. (1999) Paracetamol revisited: a review of the pharmacokinetics and pharmacodynamics. Acute Pain 2: 139–149.
89. Warren A. Le Couteur D.G. Fraser R. Bowen D.G. McCaughan G.W. Bertolino P. (2006) T lymphocytes interact with hepatocytes through fenestrations in murine liver sinusoidal endothelial cells. Hepatology 44: 1182–1190.
90. Watkins P.B. (2009) Biomarkers for the diagnosis and management of drug-induced liver injury. Sem Liver Dis 29: 393–399.
91. Wilke R.A. Lin D.W. Roden D.M. Watkins P.B. Flockhart D. Zineh I. (2007) Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov 6: 904–916.
92. Winnike J.H. Li Z. Wright F.A. Macdonald J.M. O'Connell T.M. Watkins P.B. (2010) Use of pharmaco-metabonomics for early prediction of acetaminophen-induced hepatotoxicity in humans. Clin Pharmacol Ther 88: 45–51.
93. Wynne H. (2005) Drug metabolism and ageing. J Br Menopause Soc 11: 51–56.
94. Wynne H.A. Cope L.H. Herd B. Rawlins M.D. James O.F. Woodhouse K.W. (1990) The association of age and frailty with paracetamol conjugation in man. Age Ageing 19: 419–424.
95. Wynne H.A. Cope L.H. James O.F. Rawlins M.D. Woodhouse K.W. (1989) The effect of age and frailty upon acetanilide clearance in man. Age Ageing 18: 415–418.
96. Wynne H.A. Yelland C. Cope L.H. Boddy A. Woodhouse K.W. Bateman D.N. (1993) The association of age and frailty with the pharmacokinetics and pharmacodynamics of metoclopramide. Age Ageing 22: 354–359.
97. Yamano T. DeCicco L.A. Rikans L.E. (2000) Attenuation of cadmium-induced liver injury in senescent male Fischer 344 rats: role of Kupffer cells and inflammatory cytokines. Toxicol Appl Pharmacol 162: 68–75.
98. Yue J. Peng R.X. Yang J. Kong R. Liu J. (2004) CYP2E1 mediated isoniazid-induced hepatotoxicity in rats. Acta Pharmacol Sin 25: 699–704.